Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

163.20
-2.6600-1.60%
Volume:5.72M
Turnover:932.69M
Market Cap:392.92B
PE:28.19
High:164.21
Open:163.63
Low:162.23
Close:165.86
Loading ...

2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream

Motley Fool
·
24 Feb

Flowers Foods completes acquisition of Simple Mills

TipRanks
·
22 Feb

Is Johnson & Johnson's (NYSE:JNJ) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Simply Wall St.
·
22 Feb

BUZZ-Alvotech rallies after US biosimilar launch

Reuters
·
22 Feb

Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?

Zacks
·
22 Feb

BUZZ-Protagonist Therapeutics rises on quarterly profit beat

Reuters
·
21 Feb

Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?

Insider Monkey
·
21 Feb

Johnson & Johnson's Subcutaneous Ulcerative Colitis Treatment Shows 'Significant' Improvements

MT Newswires Live
·
21 Feb

BRIEF-Tremfya Subcutaneous (SC) Induction Data Support Potential To Be The First To Offer The Option Of Both Intravenous And SC Induction Therapy In Ulcerative Colitis

Reuters
·
21 Feb

Tremfya® (Guselkumab) Subcutaneous (Sc) Induction Data Support Potential to Be the First and Only in Its Class to Offer the Option of Both Intravenous and Sc Induction Therapy in Ulcerative Colitis

THOMSON REUTERS
·
21 Feb

J&J: Safety Data From Astro Study Were Consistent With Well-Established Safety Profile of Tremfya

THOMSON REUTERS
·
21 Feb

J&J: Study Achieves Primary and All Secondary Endpoints at Week 12

THOMSON REUTERS
·
21 Feb

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

PR Newswire
·
21 Feb

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire
·
21 Feb

Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US

Reuters
·
21 Feb

Teva Pharma and Alvotech launch Stelara biosimilar in US

Reuters
·
21 Feb